Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04564274 · ClinicalTrials.gov registry record
COV2Base-A Rare Disease by COVID Study
A clinical trial, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- Completed
- Registry status
- 1,748
- Enrollment target
NCT04564274: Completed study, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
NCT04564274 is a clinical trial that has completed, run by National Heart, Lung, and Blood Institute (NHLBI). The registered enrollment target is 1,748 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04564274 has completed, sponsored by National Heart, Lung, and Blood Institute (NHLBI).
- COMPLETED
- Registry status
- 1,748 participants
- Enrollment target
Study Summary
Background: SARS-CoV-2 is the virus that causes COVID. It has caused a global pandemic. Most people have no to mild symptoms. But some people need to be hospitalized, and a small number need critical care. Older age as well as some socio-demographic factors and chronic health conditions may play a role in the severity of COVID. In this study, researchers want to assess sociodemographic-, population-, disease-, and gene-based risks for features associated with severe SARS-CoV-2 outcomes. As more is understood about COVID, researchers also want to learn more about people s experiences with COVID vaccines, long-haul symptoms, and other related disease features. Objective: To measure the frequency and severity of COVID infection in people with rare and common diseases, looking for conditions that increase risk of severe outcomes. To describe experiences with COVID vaccines, symptoms, and other features of COVID in people with rare and common diseases. Eligibility: People greater than 1 month of age, both with and without rare disease, who have access to the Internet. Design: This study will take place online. Participants will visit a website. They will fill out a survey. It should take less than 30 minutes to complete. They will answer questions about their current health and COVID experiences. They will answer questions about their demographic and location features that may impact their exposure to the virus. All questions are optional. Participants may repeat the survey if their responses indicate a need for follow-up. Participants medical records may be reviewed. Participants may be contacted for future studies related to: COVID Their underlying health conditions A new exposure that is being studied....
Primary Outcome
To quantify the frequency and severity of COVID infection in patients with rare and common diseases, looking for conditions that increase risk of severe outcomes.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,748 participants |
| Start Date | 2020-10-04 |
| Est. Completion | 2022-05-20 |
What the finished NCT04564274 record still lists
NCT04564274 is an observational study that tracks outcomes without assigning an intervention. Its 1,748 participants enrollment target places it among the larger protocols in the corpus.
The record links to 0 conditions, and to 0 interventions.
NCT04564274 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04564274 about?
NCT04564274 is a clinical study titled "COV2Base-A Rare Disease by COVID Study". Background: SARS-CoV-2 is the virus that causes COVID. It has caused a global pandemic. Most people have no to mild symptoms. But some people need to be hospitalized, and a small number need critical care. Older age as well as some socio-demographic factors and chronic health conditions may play a ...
What is the current status of trial NCT04564274?
This trial is currently completed. The enrollment target is 1,748 participants. The study started on 2020-10-04. Estimated completion is 2022-05-20.
Who is sponsoring clinical trial NCT04564274?
This trial is sponsored by National Heart, Lung, and Blood Institute (NHLBI), which has 501 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05934487 · 1,750 participants · NA
PROACTIVE-HF-2 Trial Heart Failure NYHA Class II and III
- NCT06954337 · 1,750 participants · NA
MATCH-UP: MAking Telehealth-Delivery of Cancer Care at Home Effective and Safe-Upscaled: A Pragmatic Cluster Randomized Trial
- NCT07183527 · 1,750 participants · NA
Hybrid Type I Effectiveness-implementation Cluster Randomized Controlled Trial of CARES
- NCT07062172 · 1,753 participants · NA
Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI